However, IL-18 (a pro-inflammatory cytokine) suppresses FXR activity while simultaneously activating the NF-κB/YY1 axis, contributing to the downregulation of MRP2 expression, therefore promoting cancer cells’ chemoresistance under the tumor microenvironment [130]. The gene discussed is YY1; the disease is neoplasm.